Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
- Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
- Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
December 23, 2019
- Japan OKs FY2020 Budget, Record 35.86 Trillion Yen Allotted to Social Security
December 23, 2019
- Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More
December 23, 2019
- MHLW Panel Concerned about Further Clinical Trial for Eisai’s Investigational Epilepsy Drug Following Death
December 23, 2019
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- MHLW Council Holds Off Nonprescription Switches for Domperidone, Menatetrenone
December 20, 2019
- Councilor Mori, MHLW's Top Pharmacy Officer, to Bow Out at Year-End
December 19, 2019
- Japan, China, South Korea Adopt Joint Statement on Prevention and Control of Infectious Diseases
December 19, 2019
- FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Nobel Laureate Honjo Presses for More AMED Funding for Basic Research
December 17, 2019
- Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
December 16, 2019
- Chuikyo OKs Coverage for Risk-Reducing Breast and Ovary Removal in Cancer Patients
December 16, 2019
- PMDA Reviewing Safety Risks for Cosentyx, Suglat and More
December 16, 2019
- Chuikyo Members Oppose Creation of Medical Fees for “Formularies” at Special Function Hospitals
December 16, 2019
- Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
December 16, 2019
- Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…